



Resource impact statement

Resource impact

Published: 14 December 2022

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended trifluridine–tipiracil, within its marketing authorisation, as an option for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults who have had 2 or more treatment regimens. It is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the overall incremental cost of treatment is low and the population is small.

Trifluridine–tipiracil has a discount that is commercial in confidence. For enquiries about the patient access scheme contact medical.information-uk@servier.com.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

ISBN: 978-1-4731-4900-7